138 Chapter 6 Table S1. Criteria that must be fulfilled for oral switch therapy in S. aureus bacteremia Total N=1156 North America N=399 Europe N=372 Asia N=177 Oceania N=120 South America N=70 Africa N=18 p Source control achieved 914 (79.1) 325 (81.5) 307 (82.5) 125 (70.6) 87 (72.5) 57 (81.4) 13 (72.2) <0.01 Absence of central nervous system infection 793 (68.6) 289 (72.4) 248 (66.7) 123 (69.5) 67 (55.8) 53 (75.7) 13 (72.2) 0.01 Negative blood culture 48-72h after start antibiotics 652 (56.4) 247 (61.9) 217 (58.3) 85 (48.0) 52 (43.3) 39 (55.7) 12 (66.7) <0.01 Absence of endovascular focus 558 (48.3) 202 (50.6) 173 (46.5) 93 (52.5) 45 (37.5) 31 (44.3) 14 (77.8) 0.01 Afebrile for at least 72h 644 (55.7) 206 (51.6) 224 (60.2) 91 (51.4) 64 (53.3) 49 (70.0) 10 (55.6) 0.02 No evidence of metastatic foci 573 (49.6) 217 (54.4) 167 (44.9) 101 (57.1) 41 (34.2) 42 (60.0) 5 (27.8) <0.01 Negative blood culture for at least 72h 602 (52.1) 220 (55.1) 182 (48.9) 99 (55.9) 63 (52.5) 31 (44.3) 7 (38.9) 0.2 Legend. Values are counts (% of respondents of region who answered the question). N = number of respondents that answered this question. p value refers to difference between continents.
RkJQdWJsaXNoZXIy MTk4NDMw